Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pseudomonas aeruginosa lipopolysaccharide (LPS) is a major component of the outer membrane of this Gram-negative bacterium. It plays a critical role in the organism’s structural integrity, virulence, and interactions with host immune systems. LPS is essential for bacterial survival and pathogenicity, contributing to resistance against host defenses and antibiotics. LPS consists of three main regions: Lipid A (endotoxin), core oligosaccharide, and O-antigen. As a virulence factor it protects P. aeruginosa from environmental threats including antimicrobial peptides and complement-mediated killing. Host pattern recognition receptors detect lipid A moieties through TLR4/MD2/CD14 complexes, triggering inflammatory responses that can lead to sepsis if uncontrolled. Variations in LPS structure during biofilm growth enhance bacterial persistence and resistance mechanisms within host tissues or medical devices.
Polymyxins bind to lipid A, disrupting the bacterial membrane. TLR4 antagonists block LPS-induced immune activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudomonas aeruginosa Lipopolysaccharide (LPS).